Does ROVALPITUZUMAB TESIRINE Cause Hyperammonaemic encephalopathy? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Hyperammonaemic encephalopathy have been filed in association with ROVALPITUZUMAB TESIRINE. This represents 25.8% of all adverse event reports for ROVALPITUZUMAB TESIRINE.
8
Reports of Hyperammonaemic encephalopathy with ROVALPITUZUMAB TESIRINE
25.8%
of all ROVALPITUZUMAB TESIRINE reports
0
Deaths
8
Hospitalizations
How Dangerous Is Hyperammonaemic encephalopathy From ROVALPITUZUMAB TESIRINE?
Of the 8 reports, 8 (100.0%) required hospitalization, and 5 (62.5%) were considered life-threatening.
Is Hyperammonaemic encephalopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ROVALPITUZUMAB TESIRINE. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does ROVALPITUZUMAB TESIRINE Cause?
What Other Drugs Cause Hyperammonaemic encephalopathy?
VALPROIC ACID (455)
FLUOROURACIL (156)
VALPROATE (120)
DIVALPROEX (119)
OXALIPLATIN (107)
TOPIRAMATE (101)
RISPERIDONE (96)
QUETIAPINE (91)
LEVETIRACETAM (71)
LEUCOVORIN (62)